热门资讯> 正文

BioAtla强调FDA对3期Ozuriftamab Vedotin试验设计的一致性;表示公司继续为启动3期研究做准备;公司维持先前的指导

2025-09-08 20:07

BioAtla(BCAB) 0

FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approval
Company continues preparations for enabling initiation of the Phase 3 study with the goal of advancing the study with a strategic partner early next year
Company maintains previous guidance for completion of a strategic partnership with one of our advanced clinical assets this year

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。